Tiago Marques Buys 33,333 Shares of Pasithea Therapeutics (NASDAQ:KTTA) Stock

Pasithea Therapeutics Corp. (NASDAQ:KTTA) CEO Tiago Marques bought 33,333 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were acquired at an average cost of $0.75 per share, for a total transaction of $24,999.75. Following the completion of the acquisition, the chief executive officer directly owned 73,334 shares in the company, valued at $55,000.50. The trade was a 83.33% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pasithea Therapeutics Price Performance

Shares of KTTA opened at $1.36 on Monday. The company’s 50-day moving average is $0.74 and its 200-day moving average is $0.76. The firm has a market capitalization of $10.08 million, a PE ratio of -0.27 and a beta of 0.20. Pasithea Therapeutics Corp. has a fifty-two week low of $0.28 and a fifty-two week high of $3.85.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.41) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Pasithea Therapeutics in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pasithea Therapeutics presently has a consensus rating of “Sell”.

Institutional Trading of Pasithea Therapeutics

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP acquired a new position in shares of Pasithea Therapeutics in the 3rd quarter valued at about $26,000. Citadel Advisors LLC increased its holdings in Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after purchasing an additional 20,483 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its holdings in shares of Pasithea Therapeutics by 261.5% during the 2nd quarter. AdvisorShares Investments LLC now owns 193,547 shares of the company’s stock worth $140,000 after buying an additional 140,000 shares in the last quarter. Institutional investors own 23.92% of the company’s stock.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.